SaudiVax, located in the KAUST Research & Technology Park, is collaborating with the University of Pittsburgh and Merck France to develop a COVID-19 antibody injection. The antibody both protects against potential infection and neutralizes the virus in those already infected. SaudiVax is utilizing KAUST expertise and has contracted with Merck France for manufacturing since suitable facilities are not yet available in Saudi Arabia. Why it matters: This partnership highlights the growing biopharmaceutical capabilities in Saudi Arabia and the potential for KAUST to serve as a hub for medical innovation in the region.
KAUST's Bioscience Core Lab (BCL) supports regional and global health initiatives through industry partnerships, offering expertise and technology access to organizations like SaudiVax. BCL aids SaudiVax in developing vaccines and monoclonal antibodies tailored to the needs of Saudi Arabia and the MENA region, focusing on respiratory diseases like MERS and COVID-19. SaudiVax is also collaborating with KAUST to research a new preventative drug targeting SARS-CoV-2. Why it matters: This strengthens Saudi Arabia's capabilities in vaccine development and biomanufacturing, addressing critical healthcare needs in the region and reducing reliance on external sources.
The Saudi Vaccine and Biomanufacturing Center (SVBC), the first of its kind in the Middle East, broke ground at KAUST on December 15. The center will develop vaccines and biopharmaceutical products under good manufacturing practice (GMP) standards. It is a joint project championed by the Ministry of Energy, Industry and Mineral Resources through the Industrial Clusters Program and supported by KACST. Why it matters: The center will serve as a national platform for pharmaceutical innovation and address epidemic risks in the Kingdom, such as MERS-CoV.
The Research Products Development Company (RPDC) signed an agreement with The Saudi Vaccine and Biomanufacturing Center (SVBC) to establish a research and industrial center in Saudi Arabia for vaccine and biopharmaceutical development. Supported by KACST and hosted by KAUST, the SVBC will provide a state-of-the-art facility and a training platform. Cooperation agreements were also signed with GE for equipment supply and with Fujifilm Dayosent Biotechnology for MERS-CoV treatment development. Why it matters: This initiative aims to localize vaccine and advanced treatment industries in Saudi Arabia, create technical jobs, and reduce reliance on imports in line with Vision 2030.
KAUST is joining universities worldwide to expedite licensing for COVID-19 related technologies. KAUST researchers are focusing on developing rapid diagnostic platforms, genomic analyses, and tools to track the virus's spread, collaborating with Saudi healthcare stakeholders. By signing the AUTM COVID-19 Licensing Guidelines and adopting the COVID-19 Technology Development Framework, KAUST will offer royalty-free, time-limited, non-exclusive licenses during and after the pandemic. Why it matters: This initiative facilitates quicker development and broader access to essential technologies for combating COVID-19 in Saudi Arabia and the Middle East.